Esketamine Nasal Spray Market Players:
- Eli Lilly & Company
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bristol Myers Squibb Company
- Novartis International AG
- Bausch Health Companies Inc.
- Validus Pharmaceuticals LLC
- Pfizer Inc.
- AbbVie Inc.
- Merck KGaA
- Endo International Plc
- MedKoo Biosciences, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of esketamine nasal spray is estimated at USD 28.77 billion.
The global esketamine nasal spray market size crossed USD 27.11 billion in 2025 and is likely to register a CAGR of over 6.8%, exceeding USD 52.34 billion revenue by 2035.
North America is projected to secure a 38% share by 2035 in the esketamine nasal spray market, underpinned by the escalating prevalence of depression across the region.
Key players in the market include Eli Lilly & Company, Bristol Myers Squibb Company, Novartis International AG, Bausch Health Companies Inc., Validus Pharmaceuticals LLC, Pfizer Inc., AbbVie Inc., Merck KGaA, Endo International Plc, MedKoo Biosciences, Inc., Janssen Global Services, LLC, Otsuka Pharmaceutical Co., Ltd., Biogen Inc., Sage Therapeutics, Inc.
